Press Releases May 11, 2026 08:30 AM

Disc Medicine to Participate in Upcoming Investor Conferences

Disc Medicine to Present at Upcoming Investor Conferences in May and June 2026

By Maya Rios IRON

Disc Medicine, Inc., a clinical-stage biopharmaceutical company focusing on novel treatments for serious hematologic diseases, announced its management will participate in two upcoming investor conferences, including the H.C. Wainwright BioConnect and Jefferies Global Healthcare conferences, presenting fireside chats webcasted live and available for replay.

Disc Medicine to Participate in Upcoming Investor Conferences
IRON

Key Points

  • Disc Medicine is a clinical-stage biopharmaceutical firm targeting hematologic diseases through novel therapies focused on heme biosynthesis and iron homeostasis.
  • Company management will engage investors at two major healthcare conferences to share updates and strategic insights.
  • The presentations aim to increase transparency and awareness of the company's pipeline and development progress in hematology therapeutics.

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences:

  • H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.
  • Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after each event.

About Disc Medicine

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Deerfield Group
[email protected]

Investor Relations Contact

Christina Tartaglia
Precision AQ
[email protected]


Risks

  • As a clinical-stage company, Disc Medicine's therapies are not yet approved, carrying inherent clinical and regulatory development risks.
  • Dependence on successful trial outcomes and regulatory approvals for future revenue generation affects the company's valuation and market sentiment.
  • Competitive landscape in hematologic diseases and the potential for delayed or failed drug development pose uncertainties impacting investor confidence.

More from Press Releases

Aeluma to Participate in Upcoming Investor Conferences May 12, 2026 Banzai to Host First Quarter 2026 Financial Results Conference Call on Friday, May 15, 2026 at 4:30 p.m. Eastern Time May 12, 2026 Agora, Inc. to Report First Quarter 2026 Financial Results on May 26, 2026 May 12, 2026 Auburn National Bancorporation, Inc. Declares Quarterly Dividend May 12, 2026 Highwoods Sells Bridgestone Tower in CBD Nashville May 12, 2026